Study Conduct

Report: Clinical research benefits the U.K. economy

Friday, December 2, 2016

An independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network and produced by KPMG’s Economics team, provides an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the U.K. The report includes assessment of the economic contribution made to the U.K. economy through clinical research activity supported by the network; analysis to quantify the value of payments made to NHS Trusts for commercial studies, and the value to the NHS of pharmaceuticals used as part of industry-sponsored studies.

[Read More]

AHA, Amazon launch cloud-based precision medicine data marketplace

Tuesday, November 15, 2016

The American Heart Association (AHA) announced a milestone in its strategic collaboration with Amazon Web Services (AWS)—the launch of a global, secure cloud-based data marketplace that will help revolutionize how researchers and clinicians come together as one community to access and analyze rich and diverse data to accelerate solutions for cardiovascular diseases—the No. 1 cause of death worldwide. 

[Read More]

TARGET PharmaSolutions, Bristol-Myers Squibb partner on real world data platform

Tuesday, November 15, 2016

TARGET PharmaSolutions, a clinical data company focused on real world evidence, has announced two new collaborations with Bristol-Myers Squibb to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The TARGET model provides pharmaceutical and biotechnology partners access to a robust disease state registry that is also linked to a biorepository and patient reported outcomes, providing unique data and insights compared to typical patient registries.

[Read More]

Engaging patients for a more successful clinical trial

Tuesday, November 15, 2016

Recruitment has always been a key element to a successful clinical trial, and in the past several years the concept of patient engagement—be­yond getting patients in the door—has grown. Historically for rare and orphan disease trials, engagement has helped recruit patients and make sure they are familiar with the treatments involved in the study, which makes them more willing to utilize the treat­ment once it has been approved.

[Read More]

PSR Orphan Experts launches patient organization advisory board

Wednesday, November 9, 2016

PSR Orphan Experts, a specialty orphan drug consulting and clinical research company, has announced the launch of a new Patient Organization Advisory Board to bolster its regulatory and clinical-stage drug development services in rare diseases. The advisory board comprises of up to seven experts from patient organizations, representing a wide range of therapeutic areas, and will play a key role in driving successful orphan drug programs for PSR’s clients.

[Read More]

CluePoints, Metrics Champion Consortium partner

Wednesday, November 9, 2016

CluePoints, a provider of centralized statistical monitoring (CSM) and risk-based monitoring (RBM) solutions for clinical trials, has partnered with the Metrics Champion Consortium (MCC), an association dedicated to the development of standardized performance metrics to improve clinical trials. Drawing on the company’s vast expertise in RBM, CluePoints will work with the consortium to help drive collaboration in the development of a standardized framework for Central Monitoring, including identification and definition of what is included, who should be involved, and how best to manage the process.  

[Read More]